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Objective 
The purpose of this study was to complete the data frequency and mutation profile of Hepatitis 
B Virus (HBV) pre-S1 and pre-S2 in Indonesia. 
Methods 
This cross-sectional study was used 32 blood serum samples of Chronic Liver Disease (CLD) 
patients with Hepatitis B surface antigen (HbsAg) at Endoscopy Outpatient Clinic, RSUD Dr. 
Soetomo Hospital, Surabaya. Polymerase Chain Reaction (PCR) of HBV DNA was performed 
on the samples based on pre-S1 and pre-S2 region. Then, electrophoresis was performed on the 
PCR product and followed by sequencing on samples with positive electrophoresis result. The 
sequencing results were analyzed by comparing them with the published sequences of HBV 
nucleotide. 
Results 
The amplification results of nested PCR DNA HBV with primers based on HBV pre-S1 and 
pre-S2 region were positive at 21 serums. In patients with CLD in this study, pre-S1 and / or 
pre-S2 HBV mutations were found in 11 (84.62%) chronically infected HBV patients, 4 (100%) 
patients with liver cirrhosis, and 4 (100%) HCC patients. Dominant mutations were L101V 
(16.57%), M120I / T or pre-S2 start codon (10.82%), and F141L (10.81%). M120 and F141L 
mutations have been previously reported to be associated with CLD, while the dominant L101V 
mutation in this study as well as several other mutations has not been reported in previous 
studies. 
Conclusions 
Mutations of pre-S1 and pre-S2 HBV regions were obtained in 90.48% of CLD patients in the 
form of substitution and deletion of amino acids.  
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INTRODUCTION 
 
Hepatitis B virus infection (HBV) is a serious infectious disease 
that becomes a worldwide concern. According to World Health 
Organization (WHO) data, it is estimated that more than two 
billion people worldwide have been infected by HBV. HBV is 
transmitted through blood, genital secretions, or other body fluids 
from patients infected with HBV. HBV infections could be acute 
or chronic. It is estimated that about 780,000 people die annually 
of chronic liver disease (CLD) due to HBV infection, mainly by 
cirrhosis of the liver and Hepatocellular Carcinoma (HCC) (1). In 
CLD, chronic liver damage occurs due to inflammation, necrosis, 
fibrosis, and it may progress to carcinogenesis. Clinically called 
CLD includes chronic hepatitis B, liver cirrhosis, and HCC (2). 
 According to the WHO classification, Southeast Asia 
including Indonesia belongs to areas with high HBV endemicity, 
where in this region an estimated 100 million people live with 
chronic HBV infection and 70% -90% of HBV-infected 
populations occur before age 40 (3). The estimation of HBV 
infected patients in Indonesia are to be 18 million, 10 percent of 
whom will become liver fibrosis which could then develop into 
cirrhosis of the liver as well as HCC (4). 
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 Although the pathogenesis of CLD is not fully 
understood, there are several factors suspected to affect the 
progression of HBV infection to CLD, one of which is a mutation 
in the pre-S HBV region (5). In previous studies, there has been a 
reported association between mutations in the pre-S1 and pre-S2 
HBV regions with CLD occurrence (6–9). HBV pre-S1 and pre-
S2 regions encode three HBV surface proteins: Small Hepatitis B 
surface protein (S-HBs), Middle Hepatitis B surface protein (M-
HBs), and Large Hepatitis B surface protein (L-HBs); or S 
(small), M (middle), dan L (large) proteins (10). Pre-S1 and pre-
S2 regions are highly immunogenic regions containing many B 
and T lymphocyte epitopes (11). Besides containing B and T 
epitopes, pre-S1 and pre-S2 areas also have other functional sites 
that play important roles in the attachment, replication and 
progression of viral infections (5). 
Mutations in the pre-S1 and pre-S2 regions could lead to 
the immune escape of the virus as both regions have many 
epitopes of both B and lymphocytes. Immune escape from virus 
causes persistence and chronicity of HBV infection. Mutations in 
the pre-S1 and pre-S2 regions could lead to an imbalance between 
three HBV surface proteins, Small (S), Middle (M), and Large (L) 
proteins. The portion of the L protein facing the cytoplasm serves 
to form the nucleocapsid, while the one facing the ER lumen plays 
a role in the attachment of HBV with hepatocytes (12). Of the 
three surface proteins, L protein is only expressed as much as 5-
15%, M protein as much as 1-2%, while the rest is S protein (13). 
Excessive retention of L protein in the endoplasmic reticulum 
(ER) in the absence of S and M proteins that assist its secretion 
will cause ER stress and lead to oxidative stress that could trigger 
liver damage and fibrosis (14,15). ER stress could also activate 
hepatic carcinogenesis pathways (12). 
Data on pre-S1 and pre-S2 HBV mutations in CLD 
patients in Indonesia is still very limited, thus this research was 
aimed to analyze pre-S1 and pre-S2 HBV mutation profile in CLD 
patients in Indonesia. 
 
MATERIALS AND METHODS 
 
Sampling 
 
This study was a cross-sectional study that used a thirty-two (32) 
blood serum samples obtained from chronically infected HBV 
patients with a history of positive HBsAg for more than 6 months. 
Samples were taken at Endoscopy Outpatient Clinic, RSUD Dr. 
Soetomo Hospital, Surabaya in November, 2015. This study had 
received approval from the Ethics Committee of RSUD Dr. 
Soetomo, Surabaya. Informed consent was explained and 
voluntarily signed by participants before blood sampling. Blood 
was collected into Venoject tube without anticoagulant. The blood 
serum was separated, inserted into 3 Eppendorf tubes of 1.5 mL 
and stored at minus 80ºC at the Hepatitis Institute of Tropical 
Disease (ITD) until being used. Serum HBsAg and ALT were re-
examined. Positive samples of HBsAg will be performed PCR on 
HBV DNA and positive PCR results will be sequenced for 
analysis of mutations in pre-S1 and pre-S2 regions. 
 
Examination of HBsAg and ALT 
 
ALT was checked with ALT Activity Kit with Ref No.981769 
Lot.KB33 from Thermo, Finland by colorimatric enzyme activity 
assay method, while HBsAg was checked using HBsAg ELISA 
Kit with Ref No.1231-1021b010763-01 from Acon, USA by 
ELISA method. 
 
 
Viral DNA Extraction and PCR 
 
HBV DNA extraction was performed using QiaAMP DNA Blood 
Mini Kit with Cat.No.51104 from Qiagen, Germany. The 
amplification reaction was based on the pre-S1 and pre-S2 HBV 
regions. Nested PCR DNA HBV in pre-S1 and pre-S2 based gene 
samples was carried out using a PCR Invitrogen kit with Ref 
No.25027 from Intron. In the first round reaction PCR used PS-1 
(5'-GGGTCACCATATTCTTGGGA-3') (2814-2839) and PS-2 
(5'- CCCCGCCTGTAACACGAGCA-3') (208-189) primer pair, 
which, if a negative result obtained, was followed by second-
round PCR HBV using PS-3 (5'-TTGGGAACAAGAGACACC-
3') (2828-2847) and PS-4  (5'-CACGAGCAGGGGTCCTAGGA-
3') (196-177) primer pair (16). PCR was done by using a PCR 
Thermal Cycler machine: Applied Biosystem Verity 96 Well. The 
PCR procedure began with the initial denaturation at 94ºC for 2 
min, followed by PCR cycle with the following steps of 36 cycles: 
denaturation at 94ºC for 60 seconds, annealing at 58ºC for 30 
seconds and elongation at 72ºC for 60 seconds. After the 36th 
cycle a final elongation with temperature 72ºC for 7 minutes was 
performed.  
This study also confirmed the presence of positive HBV 
DNA in samples with HBsAg positive, but still negative with PS-
1, PS-2, PS-3, and PS-4 primers. In a sample with a negative HBV 
DNA, PCR was performed using surface and core regions. The 
primers used to detect HBV DNA surface region in this study 
were P7 (256-278): 5'-GTGGTGGACTTCTCTCAATTTTC-3 
'and P8 (796-776): 5'-CGGTAWAAAGGGACTCAMGAT-3' for 
first round PCR and HBS1 (455 -474): 5'-
CAAGGTATGTTGCCCGTTTG-3 'and HBS2 (713-694): 5'-
AAAGCCCTGCGAACCACTGA-3' for the second round PCR 
(17). Primers 12F (3075-3094): 5'-
GTGGAGCCCTCAGGCTCAGG-3 'and 12R (256-237): 5'-
CGAGTCTAGACTCTGTGGTA-3' were also used for 
amplification of pre-S2 to surface area (18). The primers of core 
region used to detect the HBV DNA in this study were HBC1 
(1650-1669) 5'-TTACATAAGAGGACTCTTGG-3 'and HBC2 
(2494-2475) 5'-TAAAGCCCAGTAAAGTTTCC-3' for first 
round PCR and HBC3 (1744-1761) 5'-
GGGAGGAGATTAGGTTAA-3 'and HBC4 (2476-2457) 5'-
CCCACCTTATGAGTCCAAGG-3' for second round PCR (19). 
 
Detection of PCR products  
 
Electrophoresis was performed using 2% agarose gel run at 100 
volts, and then viewed under ultraviolet light and documented 
using a digital camera. In samples with positive PCR HBV DNA 
results, purification, labelling, and pro sequencing PCR were 
performed. 
 
Sequencing 
 
Purification of PCR products was carried out with QiaQuick Gel 
Extraction Kit Qiagen Cat. #2870. PCR labelling was done with 
Sequencing Reaction Kit (ABI Prism Big Dye Terminator vl.l 
Ready Reaction Cycle Sequencing Kit, Applied Biosystems). 
DNA Sequencing was performed using ABI Prism 310 Genetic 
Analyzer (Perkin Elmer) after previously prepared with a given 
MJBMB, 2018, 3, 85 - 92 
- 87 - 
 
Big Dye Terminator and SAM solution, heated, incubated in ice, 
and transferred into a sterile microtube. 
 
Analysis of mutations in the pre-S1 and pre-S2 regions 
 
Genotype and homology analysis with the nuclear BLAST 
nucleotide program (NCBI) was performed on the nucleotides of 
this study and the nucleotides used as a comparison. HBV 
nucleotide sequences from samples were compared with the 
sequence of HBV nucleotides obtained from international DNA 
data banks (DDBJ, GenBank, EMBL) according to the genotype 
result from BLAST. The sequence results were analyzed in the 
Clone Manager 9 computer software to determine the mutations in 
the pre-S1 and pre-S2 regions. 
 
RESULTS AND DISCUSSION 
 
A total of 32 serum samples of CLD patients from Endoscopy 
Outpatient Clinic, Dr. Soetomo Hospital, Surabaya had been 
collected in this study. All the patients showed a history of 
positive HBsAg examination in the past for more than six months 
and until the time of blood sampling for this study, HBsAg was 
still positive. 
 This study showed that CLD patients in Endoscopy 
Outpatient Clinic, Dr. Soetomo Hospital, Surabaya has the 
youngest age 14 years old and the oldest age 65 years old, with an 
average age of 46.06 years. Male CLD patients 71.88% (23/32 
people) were more than women 28.12% (9/32 people). The mean 
age of CLD patients in male patients was 46.43 years with the age 
range of 21 to 65 years, whereas the mean age in women was 
45.11 years with the age range of 14 to 65 years. This supports 
data from previous studies suggesting that HBV-infected men are 
more likely to be CLD than women (20–23). 
 In this study, the majority of CLD patients were found 
to be chronic HBV infection (65.62%), followed by liver cirrhosis 
(21.88%) and HCC (12.5%). In each CLD group, the male 
patients outnumbered the female patients. This was in accordance 
with WHO (2015) data suggesting the incidence of liver cirrhosis 
and/or HCC in patients with chronic HBV infection by 20-30%. 
HCC patients were found in small numbers because HCC patients 
have a low survival rate, which was about 5 months if without 
getting adequate therapy (24). 
 Mean age of chronic HBV infected patients was 40.52 
years with age range 14 to 65 years, mean age in patients with 
liver cirrhosis was 55 years with age range 40 to 65 years, mean 
age in HCC patients was 59,5 years old with age range 49 to 65 
years. The results of this study indicated that chronic HBV 
infected patients had younger mean and range of age than patients 
with cirrhosis of the liver and HCC. The age difference of chronic 
HBV infected patients, cirrhosis of the liver, and HCC was due to 
the progression of hepatitis B disease which takes time to become 
liver cirrhosis and HCC. Weledji et al (2014) suggests that it 
generally takes about ten years for HBV infection to develop into 
chronic, 20 years to become liver cirrhosis, more than 20 years to 
become HCC, and also it was suggested that patients with 
cirrhosis of the liver and HCC were commonly found in the range 
age 50 to 70 years (25). 
 There were 15.625% of CLD patients who have an ALT 
increment exceeding 2 times the normal value limit, 9.375% of 
CLD patients who have an ALT increase of 1 to 2 times the 
normal value, and as many as 75% of CLD patients have normal 
ALT. In chronically infected HBV patients, only 5 of 21 
individuals had ALT elevations. In patients with cirrhosis of the 
liver, none had increased ALT. In HCC patients, 3 out of 5 people 
had ALT elevation. Patients with normal ALT might be in the 
immune tolerance or immune control phase of the course of HBV 
infection (26) or in the immune clearance and the immune escape 
phase where ALT is fluctuating and not always elevated (27). 
 In the electrophoresis of PCR results of this study, of 32 
serum specimens, HBV DNA in PCR product was detected in 21 
(65,63%) serum specimens. Nineteen serum specimens gave 
positive results with PS-1 and PS-2 primers (a 595 bp HBV DNA 
band), 2 specimens gave positive results with PS-3 and PS-4 
primers (569 bp DNA band HBV) whereas 11 specimens gave 
negative results with both primer pairs, although it had been 
repeated several times either by using the same primary pair or by 
pairing PS-1 with PS-4 and PS-3 primers with PS-2. Some 
electrophoresis results showed a positive result, but dubious HBV 
DNA band, as it did not match the expected bond length. The 
sequencing results from some of these doubtful samples proved to 
be incompatible with the expected sequence. This could be due to 
a HBV DNA titer that was too low because it was possible that the 
patient has taken anti-viral drugs that suppressed previous HBV 
DNA replication. The use of anti-viral drugs as a treatment for 
HBV infection, either interferon injection or the use of oral 
nucleoside analogs could suppress HBV DNA replication so that 
undetectable DNA HBV titer could be considered a marker of 
treatment efficacy even if HBsAg remains positive (28). 
 In this study, from samples with negative HBV DNA 
using PS-1 and PS-2 primers and PS-3 and PS-4, 3 samples with 
positive HBV DNA were obtained using other primer pairs. One 
sample was positive with P7-P8 primer pair, another one sample 
was positive with HBS1-HBS2 primer pair, and one sample was 
positive by using 12F-12R primer pair. A total of eight samples 
still gave negative results with the use of 3 sets of primer pairs 
above. 
 In samples that gave positive DNA HBV amplification 
results, sequencing was performed. There was one sample that had 
not been successfully sequenced with good results although the 
result of HBV DNA through positive electrophoresis showed the 
expected band and several repetitions of sequencing had been 
performed. Mutations were determined by comparing the 
nucleotide sequences of the pre-S1 and pre-S2 genes obtained in 
this study with the nucleotides obtained by other researchers and 
published. Genotype and homology analysis with the nuclear 
BLAST nucleotide program (NCBI) was performed on the 
nucleotides of this study and the nucleotides used as a 
comparison. 
 Based on the analysis with the BLAST program, all 
samples had a high homology (99%) with the B3 genotype so that 
3 sequences of nucleotide HBV with B3 genotype which had the 
highest homology with samples to be processed with sample 
sequence, ie sequence with accession number EU92618 
(Indonesia, homology 99 %), GQ924675 (Malaysia, homology 
99%), AB219430 (Philippines, 98% homology). In a genotype 
analysis to determine the standard sequences used by the 
BLASTN program, it was found that all samples in this study had 
high homology with HBV genotype B3. Based on the results of 
other previous researchers, mutations in the form of pre-S1 and 
pre-S2 deletions were more common in other HBV genotypes (A, 
C, and D) compared with HBV genotype B (29). 
 Based on the results of multiple alignments with Clone 
Manager 9 program (Figure 1), from 20 sequenced samples, 
mutations in pre-S1 and / or pre-S2 regions were obtained in 18  
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Figure 1. Multiple alignment of HBV pre-S1 and pre-S2 regions using Clone Manager 9 software 
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samples (90%), primarily in the form of one or two nucleotide 
substitutions which resulted in amino acid changes. Most of the 
samples (55.55%) had mutation only in the pre-S1 area, followed 
by mutations in pre-S1 and pre-S2 (33.33%), and few had 
mutations in pre-S2 regions only (11. 11%). One sample had a 
mutation of 30 nucleotides (10 amino acids) deletions in the 
middle of the pre-S2 region. From samples with HBV DNA of 
positive PCR products and from sequencing results, pre-S1 and / 
or pre-S2 HBV region mutations were obtained in 84.62% of 
chronic hepatitis B patients, 100% of liver cirrhosis patients, and 
100% of HCC patients. CLD patients with the highest number of 
mutations were two patients with liver cirrhosis who each had 6 
different mutations. HCC patients had 1 to 2 types of mutations in 
which all three HCC samples in this study all had L101V 
mutations. In contrast to previous studies (5,16,30), HCC patients 
in this study had no mutations in the form of deletions, however a 
mutation of L101V was obtained. 
 Mapping of mutations in this study showed that all 
successful sequencing samples had mutations in the epitope of B 
lymphocytes. Many mutations occurred in epitopes of T 
lymphocytes and pre-S1 functional areas and / or pre-S2 HBV. 
Only one mutation (Q82S) occurred in the pre-S functional area 
without concerning the epitope areas of B and or T lymphocytes. 
In this study, the affected pre-S functional areas include the 
Hsc70, CAD, nucleocapsid binding regions, the binding region of 
the hepatocytes, transactivator domain, S-promoter, pre-S2 start 
codon, as well as pHSA binding region. This is consistent with 
previous studies showing that pre-S1 and HBV pre-S2 mutations 
generally include epitopes against B and T lymphocytes and then 
trigger mutations in pre-S functional areas (14,31). 
 The dominant type of mutation in this study was the 
substitution of Leusin amino acid at position 101 to Valin 
(L101V) found in 13 of 21 samples of CLD patients (61.9%), 
followed by substitution of pre-S2 start codons (amino acid 120 
position) to threonin or isoleucine (M120I / T) found in 5 of 21 
CLD patients (23.8%), and substitution of Amino acid Fenilalanin 
at 141 to leucine (F141L) found in 4 of 21 CLD patients (19.04 
%). 
 Previous studies have shown that mutations in the pre-
S1 and pre-S2 HBV regions are found in many CLD patients 
(30,32,33). The frequency of pre-S1 and pre-S2 HBV mutations in 
CLD patients is high in hepatitis B endemic countries (34). Other 
results suggest that the HBV mutation in the form of amino acid 
substitution at various nucleotide sites is found up to 75.7% in 
CLD patients (5). Based on the mapping done by Zhang et al 
(2015), mutations in the pre-S1 and pre-S2 HBV regions may 
interfere with the recognition of immune epitopes and cause 
functional impairment of HBV surface protein when they occur in 
epitopes against B cells (aa 12-53 , aa 72-78, aa 94-117, aa 120-
143, and aa 157-167), epitopes against T cells (aa 21-30, aa 52-67, 
aa 120-145, and aa 163-172), pre-S1 start codons (aa 1), S 
promoter (nt 3045-3180), CCAAT box binding factor binding site 
(nt 3137-3141), topological domains covering Hsc70 (aa 74-118) 
and CAD (aa 81-105) binding sites, nucleocapsid binding sites (aa 
103-127), pre-S2 start codons (aa 129), and pHSA (aa 122-135). 
 Mutations in the pre-S region are found to be deletions, 
although there are a few researches that suggest mutations in the 
form of amino acid substitutions at different sites. In a study 
conducted by Zhang et al (2015) on CLD patients, there were 
many point mutations in the pre-S1 and / or pre-S2 regions in the 
form of amino acid substitutions in some codons, ie W4, D27G, 
N51Q, D54A, V60, A62S , Q100, T125S, R137, S166, and 
K167R (5). Mutation at codon 125 in the study was also obtained 
in this study. A study conducted by Chien et al (2008) mentions a 
mutation of amino acid substitution at codons 4, 7, and 81 of the 
pre-S1 region and the pre-S2 start codon in HCC patients (35). In 
another study conducted by Yin et al (2010) mentioned the 
substitution of codons 4 and 60 of pre-S1 in CLD patients (36). 
 In this study, the dominant type of mutation was the 
substitution of Leusin amino acid at position 101 to Valin 
(L101V), followed by substitution of pre-S2 start codon (M120I / 
T), and substitution of amino acid F141L. This type of L101V 
mutation has not been reported in previous studies. In this study, 
100% (3 of 3) patients with HCC had L101V mutations. 
 In this study, there was only one mutation in the form of 
pre-S2 deletion of 30 nucleotides in the middle of the pre-S2 
region in patients with cirrhosis of the liver. This is consistent 
with Chen et al's (2006) study showing that in HBV with genotype 
B, fewer deletion mutations were obtained than genotype C (6). 
The study conducted by Utama et al (2011) also reported the 
frequency of pre-S1 deletions and/or pre-S2 was low in CLD 
patients in Indonesia (30). Based on research conducted by Kim 
(2014), deletions in the pre-S2 region of HBV are known to play a 
role in the transition of chronic HBV infection to liver cirrhosis 
(37). Another study by Su et al (2014) reported that on the 
dissection of hepatic liver cirrhosis, there was a deletion in the 
dominant pre-S2 region in the nucleotide region of the 2-57 pre-
S2 regions, with or without the M120 mutation. Deletions in the 
nucleotide region 2-57 pre-S2 region cause decreased synthesis of 
S and M proteins as well as an increase in L protein causing the 
formation of Ground Glass Hepatocyte (GGH) in hepatocytes and 
causing liver fibrosis (38). 
 In a study conducted by Mun et al (2011), a mutation of 
F141L was associated with CLD risk and was significantly 
associated with M120 mutations in the pathogenesis of CLD. 
F141L and M120 double mutations can enhance the pathogenic 
ability of HBV and help HBV maintain its viral life cycle. The 
combination of F141L and M120 has a higher cell proliferation 
capacity than a single mutation. It is said that F141L mutations did 
not occur simultaneously with pre-S2 deletions (9). This was in 
line with the results of this study wherein a sample of liver 
cirrhosis having a pre-S2 deletion no F141L mutation was found. 
 The M120 mutation located in the pre-S2 start codon 
was a frequent mutation in previous studies (12,29,34). Mutations 
in the pre-S2 start codon may interfere with M protein synthesis, 
thus impairing the balance of the S, M, and L protein ratios. The 
decreased M protein leads to increased and retention of the L 
protein until ER stress arises. This leads to mutations in the pre-S2 
start codons reported to be associated with CLD, especially in 
patients with cirrhosis of the liver (29,39). 
 Other mutations found in this study were amino acid 
substitutions in codons 25, 40, 74, 82, 94, 96, 114, 115, 121, 125, 
127, 134, 142, and 149. Based on a study conducted by Lin et al 
(2013), amino acid substitution occurring in the pre-S region 
might cause changes in the immune target region when it concerns 
the epitope of lymphocytes B and or T resulting in immune-escape 
conditions, disturbance of introduction by class II MHC-
dependent helper T cells or reduce the affinity of the class I MHC 
binding on the hepatocyte surface (40). Grottola et al (2002) 
showed that the number of pre-S2 mutations was associated with 
recurrence of HBV infection after liver transplantation 
independent of immunoglobulin prophylaxis (41). Variations of 
mutations in the pre-S1 and pre-S2 regions might alter the overall 
conformation of the HBV surface protein, altering the antigenic 
MJBMB, 2018, 3, 85 - 92 
- 90 - 
 
properties of HBV against anti-HBs and causing the progression 
and chronicity of HBV infection (40). Other than that, studies in 
molecular field show that pre-S mutant interacts with many 
signalling proteins in cell cycle, cell survival, apoptosis resistance, 
genetic instability, and cell proliferation (42). 
 In HBV infection, in the event of mutations that may 
cause epitope functional disruption of B cells and T lymphocytes, 
immune escape from the virus might result in HBV replication 
and further liver damage. Mutations in the epitope region against 
B and T lymphocytes might also cause further mutations in other 
regions of pre-S1 and pre-S2 (14,35). 
 Mutations in Hsc70 or CAD causes L proteins unable to 
maintain their topological structure, as both Hsc70 and CAD are 
important determinants for maintaining the double topological 
structure of protein L (43). This will lead to the retention of L 
proteins and subvirus particles in the ER due to non-secretion 
(44). 
 Disorders in S promoter could suppress S protein 
production and cause a disruption of the balance ratio between 
protein S and protein L. Normally, L protein requires S protein to 
be secreted out of ER. When S protein production decreases, there 
could be retention of L protein in ER that can cause stress of ER 
(45,10). It was reported in a previous study by Zhang et al (2015) 
that point mutations in the S promoter region might cause a 
reduction in HBV surface protein that leads to intracellular 
retention of viral envelope proteins and causes ER stress (5). 
 Nucleocapsid binding regions were important for viral 
maturation so that virus particles and components could be 
secreted out of the ER without causing ER stress (16). Mutations 
in pHSA could cause M-protein synthesis disturbances thereby 
altering the balance of S, M, and L protein ratios to also cause ER 
stress (31). 
  Studies on the incidence of pre-S1 and pre-S2 
mutations of HBV in CLD patients in Indonesia were previously 
performed by Utama et al in 2011. In the study, it was reported 
that mutations in the form of deletions and insertions in pre-S1 
and pre-S2 HBV were only found in 12.1% of CLD patients. The 
incidence of pre-S1 and pre-S2 HBV mutations in the study was 
said to be very low when being compared with other Asian 
countries (30). It was consistent with this study, in which a pre-S2 
deletion mutation was found in only 5% of CLD patients. In a 
study also conducted by Utama et al in 2012, it was reported that 
the frequency of pre-S2 start codon mutation (M120) was quite 
high (22%), especially in patients with liver cirrhosis and HCC. In 
this study, M120I / T mutations were quite frequent (20%) but not 
found in HCC. Other mutations reported in Utama et al (2012) 
were T130 (26.1%), Q132 (28.7%), and A138 (29.5%) (46). 
 There were several factors that affect the progression of 
HBV to CLD, including host factors, viral factors, and other 
factors. Host factors include age, sex, and immune status. Viral 
factors include HBV genotype, viral load, pre-S mutation, and 
T1762 / A1764 mutations. Other factors include co-infection, 
aflatoxin, cigarette smoke, and alcohol. Virus factors could 
mutually influence each other so that there could be different 
mutation patterns between genotypes or double mutation which 
have the different influence to the incidence of CLD (47). 
 So far, studies on pre-S1 and pre-S2 mutations of HBV 
in CLD patients in Indonesia were still limited and no research 
had been found in other regions in Indonesia, so there was still 
possibility of genotypic distribution in Indonesia causing various 
frequency and types of different pre-S1 and pre-S2 HBV 
mutations in different regions. 
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